SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rocket-thruster Roadster demonstration drove intense discussion, but traders largely framed the sharp reversal after an initial pop as a sell the news reaction, questioning the cars practicality and near-term earnings impact. Some see the demo as an impressive technology showcase and speculate it could strengthen a TeslaSpaceX merger case, though no merger has been announced; broader weakness in tech stocks also weighed on shares.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a broader semiconductor selloff as investors question the sustainability and financing of AI spending; traders also cite CEO Hock Tans comments about capital constraints and speculative AI investing as adding to the pressure. The community is split between bearish concerns about AI demand and the remarks impact, and bulls who see the decline as a sector-wide pullback and continue to buy on weakness.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp, high-volume selloff with no reported company-specific news has focused discussion on suspected options-expiration pressure near the $10 strike and weakness across biotech stocks. Traders remain focused on the delayed 80th-event update and eventual Phase 3 REGAL data, with bullish dip-buyers viewing the decline as technical while skeptics cite the prolonged quiet period and uncertainty around the trial.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs steep selloff amid a broader AI-infrastructure pullback is driving attention, with traders debating whether sector weakness and lingering governance and export-control concerns outweigh the appointment of new CFO Mark Long. Some view the decline as an overdone buying opportunity, while others expect further weakness and question managements credibility.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals steep decline is being discussed amid a broader storage and AI-hardware selloff, with traders citing Toshibas planned HDD capacity expansion and Wells Fargos price-target cut as sources of pressure. Some see the concerns as overblown given AI-driven storage demand and upcoming earnings, while others point to continued selling and weak technical momentum.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

CHPY is drawing attention amid a semiconductor and technology selloff, with traders linking its decline to weakness in chip stocks and concerns about the AI trade. Some investors are buying the dip for the ETFs weekly distributions, while others question payout sustainability and warn that falling semiconductor prices can pressure its share value.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXYs sharp gain has sparked bets on a broader volatility spike, with traders pointing to market weakness and concerns about rates, oil, and geopolitical risks. Views are divided: some expect volatility to climb further, while others see a short-lived pop and cite the ETFs futures exposure and decay as reasons to fade rallies.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

OUST is drawing attention after a sharp pullback alongside weakness in AI and growth stocks, with traders debating whether the decline is an overreaction or a sign of further downside. Many are buying or averaging down, while others point to the stocks volatile trading and weakening chart.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

A sharp pullback in biotech stocks, reflected in weakness across the XBI, is driving attention to LABU, whose 3 leverage magnifies sector moves. Traders debate whether the declineoften linked in the discussion to inflation and higher-rate concernsis a buying opportunity or the start of further losses, with some favoring LABD or short trades.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABDs gain is drawing attention as traders position for further biotech weakness, citing XBIs decline and concerns that hot inflation data and higher rates could pressure the sector. The bearish view is contested by traders expecting a biotech rebound, with many emphasizing the sharp swings and decay risk of the leveraged inverse ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31R Bispecific Antibody, for Atopic Diseases

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the companys internally developed interleukin-13 (IL-13) and interleukin-31 (IL-31)R bispecific antibody, will be shared for the first time at the American College of Allergy...

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for...

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint...

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2026, along with recent product highlights and corporate updates. Zai Lab is entering an exciting new chapter in our evolution, said Dr. Samantha Du, Founder, Chairperson and Chief Executive...

U.S. FDA Grants Orphan Drug Designation to Zai Labs DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Companys potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for...

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2026 financial results and provide recent corporate updates on August 6, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m...

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy...

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Companys potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Zai Lab Limited - ADR

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$23.19
Prev Close	$23.51
Open	$24.55
Dividend Yield	0.00%
50-Day Moving Average	$25.28
Beta	1.07
Avg. Volume	849,926.20
PE Ratio	-13.81

52-Week High	$29.77
52-Week Low	$15.96
Market Capitalization	$2.65B
EPS (Annual)	-$1.61
Price to Book	4.35
Revenue Per Employee	$258,617.15

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZLAB Fundamentals